CoreBiome: Rebiotix and CoreBiome Collaborate on Evaluating Microbiomes of Patients Treated with Microbiota Restoration Therapy

Rebiotix Inc., a clinical-stage microbiome company focused on harnessing the power of the human microbiome to treat debilitating diseases, announced today its successful first phase of collaboration with CoreBiometo measure the ability of RBX2660 and RBX7455 to rehabilitate the human microbiome impacted by recurrent Clostridium difficile (C. diff) infection. CoreBiome is a genomics platform company focused on accelerating microbiome innovation with expert genomics and big-data analytics.